The platform uses Optina’s cerebral amyloid predictor retina scan and metabolic hyperspectral retinal camera to formulate a data-rich image from a basic eye scan. AI then analyzes the image for indication of amyloid plaques in the brain, which are linked to neurodegenerative diseases such as Alzheimer’s.
Optina’s technology offers a low-cost, non-invasive way to improve diagnosis accuracy and subsequent care management for patients with cognitive decline, a condition that can often go un- or misdiagnosed.
The FDA’s “Breakthrough Device” designation is not a safety approval but provides an expedited pathway for the review of a medical device that the agency believes has the potential to be extremely effective in diagnosing or treating life-threatening diseases.
More articles about AI:
Harvard Business Review: Look at AI as a system-wide update, not a point solution
Catasys will use AI, human interaction to address loneliness epidemic
MATTER, rMark Bio unveil matchmaking service to pair tech startups with healthcare clients
